Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Innovations in Microfluidics 2020

Roger Kamm's Biography



Roger Kamm, Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering, Massachusetts Institute of Technology (MIT)

Kamm is currently the Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering at MIT, where he has served on the faculty since 1978. Kamm has long been instrumental in developing research activities at the interface of biology and mechanics, formerly in cell and molecular mechanics, and now in engineered living systems. Current interests are in developing models of healthy and diseased organ function using microfluidic technologies, with a focus on vascularization. Kamm has fostered biomechanics as Chair of the US National Committee on Biomechanics (2006-2009) and of the World Council on Biomechanics (2006-2010). Kamm currently directs the NSF Science and Technology Center on Emergent Behaviors of Integrated Cellular Systems. He is the 2010 recipient of the ASME Lissner Medal (American Society of Mechanical Engineering) and the 2015 recipient of the Huiskes Medal (European Society of Biomechanics), both for lifetime achievements, and is the inaugural recipient of the ASME Nerem Medal for mentoring and education. He was elected to the National Academy of Medicine in 2010. Kamm is co-founder of two companies, Cardiovascular Technologies and AIM Biotech, a manufacturer of microfluidic systems for 3D culture.

Roger Kamm Image

Emergent Engineering of Human Neurological Disease Models

Monday, 23 March 2020 at 10:00

Add to Calendar ▼2020-03-23 10:00:002020-03-23 11:00:00Europe/LondonEmergent Engineering of Human Neurological Disease ModelsInnovations in Microfluidics 2020 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Microphysiological models have now been developed for a variety of single organs, as well as multi-organ systems.  These models are also beginning to find useful applications in the pharmaceutical and biotech industry as disease models and for intermediate throughput drug screening.  The current models range from those that are generated by precisely seeding in a device populations of fully differentiated or primary cells that then assemble into functional monolayers or simple 3D structures on one extreme, to ones that are fully emergent, forming by self-assembly often within a single cluster of pluripotent cells on the other.  We refer to these two approaches as ‘top-down engineering’ and ‘emergent engineering’.  In this presentation, the full range of techniques will be discussed, with examples derived from applications in the context of neurological function and disease.


Add to Calendar ▼2020-03-23 00:00:002020-03-24 00:00:00Europe/LondonInnovations in Microfluidics 2020Innovations in Microfluidics 2020 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com